Testosterone May Help Men With Multiple Sclerosis
Men With Multiple Sclerosis
Clinical trial now underway to confirm that the female hormone estriol combats the effects of multiple sclerosis in women, a recently completed UCLA pilot study shows promise for the use of testosterone to combat the effects of the disease in men.
Reporting in the May issue of the journal Archives of Neurology, Dr. Rhonda Voskuhl, director of UCLA's Multiple Sclerosis Program, and her colleagues found that the application of a testosterone gel reduced symptoms, slowed brain degeneration and increased muscle mass in men with relapsing-remitting multiple sclerosis, the most common form of the disease. Testosterone also has been shown to protect against an MS-like condition in animals.
Multiple sclerosis is a progressive disease involving the immune and central nervous systems. Like many other autoimmune diseases, in which the body attacks its own systems or tissues, MS is less common in men than in women, said Voskuhl, with a ratio of about three women to one man. Voskuhl has long thought that sex hormones and/or sex chromosomes may be responsible for this enhanced susceptibility.
Voskuhl and Dr. Nancy L. Sicotte, UCLA assistant professor of neurology, conducted a study of testosterone treatment in 10 men with relapsing-remitting MS, which is characterized by periods of neurologic symptoms, such as numbness or difficulty walking, followed by periods of remission. After enrollment in the study, the men, whose average age was 46, entered a six-month pre-treatment phase, during which symptoms were monitored but no therapies were administered. After that, each man applied 10 grams of a gel containing 100 milligrams of testosterone to his upper arms once daily for 12 months.
"After a year, we saw an improvement in cognitive performance and a slowing of brain deterioration," Voskuhl said. In fact, during the final nine months of gel application, the rate of brain deterioration in the men slowed by 67 percent.
In addition, the men's muscle mass increased an average of 1.7 kilograms, about 3.74 pounds, during the treatment phase. There were no reported adverse effects.